Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Alephoson Biopharmaceuticals Limited has 1 pending office action currently active. This action is assigned to 1 distinct examiner, COFFA, SERGIO. The data shows 0 distinct art units associated with this portfolio.
COFFA, SERGIO serves as the busiest examiner for the company, managing the pending office action. With only the pending workload, the prosecution path is entirely dependent on this specific examiner's review. The absence of a recorded art unit suggests a unique classification for this specific matter. Practitioners should monitor the 0 distinct art units field for any updates as the Alephoson Biopharmaceuticals Limited application progresses. This centralized structure ensures that all current legal efforts are directed toward a point of contact within the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COFFA, SERGIO | 1 | 61.2% | +32.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18580492 | CONJUGATE OF CELL-PENETRATING PEPTIDE AND MELPHALAN, AND PREPARATION CONTAINING CONJUGATE | COFFA, SERGIO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18580492 | CONJUGATE OF CELL-PENETRATING PEPTIDE AND MELPHALAN, AND PREPARATION CONTAINING CONJUGATE | COFFA, SERGIO | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18580492 | CONJUGATE OF CELL-PENETRATING PEPTIDE AND MELPHALAN, AND PREPARATION CONTAINING CONJUGATE | COFFA, SERGIO | 1658 | §103§112 | Non-Final OA | — | Pending | Jan 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlephoson Biopharmaceuticals Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sergio Coffa has the most, with 1 of Alephoson Biopharmaceuticals Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.